-

02:06:33 PM

AVIR Stock News

AVIR - Atea Pharmaceuticals Inc

09/06/23 7:00 AM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team

RHEA-AI

very negative

08/08/23 4:05 PM

Nasdaq : AVIR

earnings

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment Enrollment continues in Phase 2 trial evaluating

RHEA-AI

neutral

08/01/23 7:00 AM

Nasdaq : AVIR

conferencesearnings

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and

RHEA-AI

neutral

06/15/23 7:00 AM

Nasdaq : AVIR

clinical trial

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and

RHEA-AI

neutral

06/05/23 4:20 PM

Nasdaq : AVIR

conferences

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief

RHEA-AI

very negative

05/30/23 7:00 AM

Nasdaq : AVIR

management

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral

RHEA-AI

neutral

05/23/23 4:05 PM

Nasdaq : AVIR

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of Atea for $5.75 per share in cash, plus a

RHEA-AI

neutral

05/08/23 4:05 PM

Nasdaq : AVIR

earnings

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2Q23;

RHEA-AI

neutral

05/01/23 4:05 PM

Nasdaq : AVIR

conferencesearnings

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and

RHEA-AI

neutral

04/25/23 7:00 AM

Nasdaq : AVIR

covid-19

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the United States Food and Drug

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

AVIR Data

IndustryPharmaceutical Preparation Manufacturing
Websiteateapharma.com
Security nameAtea Pharmaceuticals Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Major

About Atea Pharmaceuticals Inc

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.